Patent · US Active

Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks

US8030097B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

Versitech Limited and R & C Biogenius Limited · CN

Inventors

Aimin Xu · Sha Tin, CN
Yu Wang · Auckland, NZ
Reinhard Renneberg · Hong Kong, CN
George William Hunter Cautherley · Kowloon, CN
Cangel Pui Yee Chan · Yuen Long, CN
Matthias Lehmann · Braunschweig, DE

Key dates

Filing date	Apr 30, 2008
Grant date	Oct 4, 2011
Priority date	—
Expiry date	Apr 30, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S436/811
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.